Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer
oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]
AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.
Related Stories
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 5 wks
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 5 wks
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 6 wks
Common asthma drug may overcome immunotherapy resistance in cancers / 7 wks
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 7 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Animal Health, Government Policy, Food Safety, Oncology and look for the RSS link.
StackHealth Time Machine